Intramuscular methylprednisolone controlled polymyalgia rheumatica with a lower steroid burden
Oral corticosteroids remain effective for polymyalgia rheumatica, but long exposure often brings a familiar trade-off: symptom relief at the cost of cumulative steroid toxicity. In this prospective study, investigators tested whether depot methylprednisolone given intramuscularly could preserve clinical control while reducing total steroid exposure over 12 months.
The cohort was small, with 16 patients, yet the treatment strategy was direct and clinically practical. Remission was achieved using 120 mg of methylprednisolone every three weeks for 12 weeks, then maintained with monthly injections on a reducing dose schedule. The regimen was designed to move disease activity down quickly and then hold remission with progressively less steroid, rather than exposing patients to the sustained daily dosing that often drives glucose intolerance, mood changes, hypertension, fluid retention, and bone loss.
One sentence captures the clinical appeal: remission came without the burden of daily oral prednisone.
Remission was achieved early and then sustained on a tapering injection schedule
The early phase of treatment carried the heaviest pharmacologic load. Every-three-week injections for 12 weeks produced remission in the study population, and that response opened the door to a maintenance approach built around less frequent dosing. Monthly injections, then reduced dosing over time, were enough to preserve remission through the 12-month observation period. In practical terms, the treatment plan mirrors a biologically sensible strategy for an inflammatory syndrome that is highly steroid responsive but vulnerable to relapse when the anti-inflammatory effect is withdrawn too abruptly.
Polymyalgia rheumatica is driven by systemic inflammatory activity that manifests as pain and stiffness, often with dramatic improvement after corticosteroid exposure. Depot intramuscular delivery can sustain glucocorticoid effect without the peaks and troughs of repeated oral dosing, and that pharmacokinetic steadiness likely helped maintain symptom control while total exposure remained lower. A lower cumulative dose matters because steroid harm is dose dependent; reducing the total amount administered over time should, in theory, reduce the probability of treatment-related complications.
No hypothalamic-pituitary-adrenal suppression appeared at 12 weeks
The most clinically reassuring safety finding was the absence of hypothalamic-pituitary-adrenal axis suppression at 12 weeks after treatment initiation. For a steroid regimen to be credible in everyday practice, it must do more than suppress symptoms. It must avoid pushing the adrenal system into clinically meaningful suppression, especially when treatment is intended to continue over months.
Here, the absence of measurable suppression at the 12-week mark suggests that this depot schedule may preserve endocrine safety better than some traditional oral approaches, at least early in treatment. The result does not eliminate the need for caution. Adrenal suppression can emerge with longer exposure, higher doses, or individual susceptibility. Still, the finding supports the biological plausibility of a regimen that balances anti-inflammatory potency with a reduced systemic steroid burden.
The safety profile was described as good, and the treatment was well tolerated over one year. For a disease that often affects older adults, tolerability is not a minor consideration. Patients with polymyalgia rheumatica frequently carry comorbidities that make prolonged oral corticosteroid therapy especially problematic, so any regimen that limits cumulative exposure deserves careful attention.
Why depot delivery could matter in everyday care
The logic behind depot intramuscular methylprednisolone is straightforward. Oral corticosteroids provide flexible dosing, but they also encourage chronic exposure, frequent dose adjustments, and prolonged systemic effects. An intramuscular depot formulation offers a different pattern: a scheduled, clinician-controlled dose that may reduce the temptation or need for long maintenance regimens at higher cumulative totals.
That approach could be particularly relevant in polymyalgia rheumatica, where treatment often extends for months and sometimes longer. If remission can be achieved with intermittent injections and maintained with tapering depot doses, the patient may avoid some of the toxicity associated with continuous daily oral therapy. Bone loss, diabetes worsening, weight gain, insomnia, hypertension, and proximal myopathy all remain practical concerns in this population, and each one becomes more likely as cumulative corticosteroid dose rises.
The study does not prove superiority over oral prednisolone. It does show that an alternate steroid delivery strategy can work, and that it can do so with a lower cumulative dose than conventional oral treatment. That is a meaningful signal in a disorder where clinicians constantly balance rapid symptom relief against the downstream consequences of steroid exposure.
Small sample, promising signal, and a controlled trial still needed
The cohort was prospective but small, and the follow-up design leaves important questions unresolved. Sixteen patients are enough to generate a signal of efficacy and tolerability, not enough to settle comparative effectiveness. The study also did not provide a controlled head-to-head estimate of relapse rates, longer-term adrenal safety, or comparative adverse-event rates versus oral prednisolone.
Even so, the findings justify the planned next step: a controlled trial comparing intramuscular methylprednisolone with oral prednisolone for polymyalgia rheumatica. That comparison should clarify whether the depot approach can reliably match the symptom control expected from oral treatment while delivering a safer steroid exposure profile. The key issue is not whether corticosteroids work, because they clearly do. The issue is how to preserve that efficacy while reducing the cumulative harm that often follows months of oral therapy.
For now, the study offers a practical therapeutic concept with real bedside implications. Depot methylprednisolone achieved remission, sustained it on a tapering schedule, and avoided detectable adrenal suppression at 12 weeks, all while keeping the cumulative steroid burden lower than standard oral regimens. Those are the features that matter when a common inflammatory syndrome collides with the long tail of steroid toxicity.